Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory
- 6 May 2016
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (8) , 1456-1466
Abstract
As survival has improved for patients with metastatic colorectal cancer (mCRC), there is an increasing need for effective and well-tolerated third-line and subsequent-lines of treatment. Despite recent advances with the development of new-targeted therapies in this setting, there remains an unmet need to exploit oncogenic drivers of colorectal cancer and overcome acquired resistance. Potential treatment strategies include revisiting old targets such as human epidermal growth factor receptor 2, RAS, and BRAF and investigating new targets such as c-MET, the PI3 kinase, and Wnt pathways, and also the use of immune-checkpoint inhibitors. Here, we review recent phase III trials exploring approved agents, early trials investigating new drugs for chemorefractory mCRC, and the potential of capturing tumour dynamics during its evolution by liquid biopsy analysis.Keywords
This publication has 108 references indexed in Scilit:
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialThe Lancet Oncology, 2013
- Recurrent R-spondin fusions in colon cancerNature, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- HER-2/neu overexpression is an independent prognostic factor in colorectal cancerInternational Journal of Colorectal Disease, 2006